Legend Biotech, a biotechnology company developing novel therapies to treat life-threatening diseases, has entered into an exclusive, global license agreement with Novartis Pharma.
The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.
Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.
